Taken together, our findings indicate that combining biomarkers of cGAS-STING activity, CIN, and neoantigen burden may improve response prediction to immunotherapy and potentially broaden the score of eligible patients by identifying small subsets of highly sensitive patients within cancer histologies that commonly fail to respond to immunotherapy. This evidence concerns the gene CGAS and cancer.